Equity Profile

NTRA

NATERA INC

Health CareBiotechnology$30.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in reproductive health and oncology....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will help gauge how well Natera is managing its costs and generating revenue.

N/A

Revenue Growth

Investors will be looking for signs of revenue growth to assess the company's market demand and overall business health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NTRA Q2-2026 Earnings Preview

Context

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in reproductive health and oncology. With a market cap of $32 billion, Natera plays a significant role in the healthcare sector, leveraging advanced technology to provide insights into genetic conditions and cancer detection.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-25.11%

Avg Stock Reaction

+1.61%

Last Quarter Recap

In Q1 2026, Natera reported an EPS of -$0.60, missing expectations by 12.78%. Despite the miss, the stock rose by 2.20% the following day, indicating some investor optimism.

Management Promises & Guidance

Focus on expanding test offerings in oncology.
Commitment to improving operational efficiency.
Plans to enhance customer engagement strategies.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Natera has struggled with profitability but continues to show potential for growth in its testing services.

Bull Case

If Natera can demonstrate significant revenue growth and improve its EPS, it could attract more investor interest and drive the stock price higher.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports widening losses, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected test volume for the upcoming quarter?

Test volume is a direct indicator of demand for Natera's services and will be critical for assessing future revenue growth.

How is Natera addressing its profitability challenges?

Investors will want to hear specific strategies for improving margins and reducing losses to regain confidence in the company's financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Natera's potential for revenue growth in oncology, given recent advancements in their testing capabilities.

Supporting Evidence

Options are pricing a 14.15% move, suggesting traders expect significant volatility.

Natera's recent focus on expanding its oncology testing could lead to higher demand than anticipated.

Insider selling may indicate a lack of confidence in the short-term outlook, contrasting with potential long-term growth.

Key Risk

If test volume exceeds expectations, it could shift sentiment dramatically and invalidate current cautious projections.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Natera's ability to grow its test volume while managing costs effectively.

Bull Confirmed If

A test volume increase of over 20% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in test volume or a wider EPS loss than expected would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.15%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±14.2% while NTRA has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.3%

Calls (19K)P/C Ratio: 0.17Puts (226K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$299,440.95

1,500 sh

1 insider

Net

$299,440.95

Net selling

Most Active Insiders· 2 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Natera beats expectations, history suggests a potential stock increase of around 1.81%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see muted movement as investors reassess future growth prospects.

Miss

A miss could lead to a decline, with history suggesting an average drop of about 1.41%, reinforcing concerns about profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the expansion of oncology test offerings.
2Details on operational efficiency improvements.
3Insights into customer engagement strategies.
4Any commentary on competitive positioning in the market.
5Guidance on expected test volumes for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in reproductive health and oncology....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will help gauge how well Natera is managing its costs and generating revenue.

N/A

Revenue Growth

Investors will be looking for signs of revenue growth to assess the company's market demand and overall business health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NTRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-25.11%

Avg Stock Reaction

+1.61%

Last Quarter Recap

In Q1 2026, Natera reported an EPS of -$0.60, missing expectations by 12.78%. Despite the miss, the stock rose by 2.20% the following day, indicating some investor optimism.

Management Promises & Guidance

Focus on expanding test offerings in oncology.
Commitment to improving operational efficiency.
Plans to enhance customer engagement strategies.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Natera has struggled with profitability but continues to show potential for growth in its testing services.

Bull Case

If Natera can demonstrate significant revenue growth and improve its EPS, it could attract more investor interest and drive the stock price higher.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports widening losses, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected test volume for the upcoming quarter?

Test volume is a direct indicator of demand for Natera's services and will be critical for assessing future revenue growth.

How is Natera addressing its profitability challenges?

Investors will want to hear specific strategies for improving margins and reducing losses to regain confidence in the company's financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Natera's potential for revenue growth in oncology, given recent advancements in their testing capabilities.

Supporting Evidence

Options are pricing a 14.15% move, suggesting traders expect significant volatility.

Natera's recent focus on expanding its oncology testing could lead to higher demand than anticipated.

Insider selling may indicate a lack of confidence in the short-term outlook, contrasting with potential long-term growth.

Key Risk

If test volume exceeds expectations, it could shift sentiment dramatically and invalidate current cautious projections.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Natera's ability to grow its test volume while managing costs effectively.

Bull Confirmed If

A test volume increase of over 20% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in test volume or a wider EPS loss than expected would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.15%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±14.2% while NTRA has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.3%

Calls (19K)P/C Ratio: 0.17Puts (226K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$299,440.95

1,500 sh

1 insider

Net

$299,440.95

Net selling

Most Active Insiders· 2 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Natera beats expectations, history suggests a potential stock increase of around 1.81%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see muted movement as investors reassess future growth prospects.

Miss

A miss could lead to a decline, with history suggesting an average drop of about 1.41%, reinforcing concerns about profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the expansion of oncology test offerings.
2Details on operational efficiency improvements.
3Insights into customer engagement strategies.
4Any commentary on competitive positioning in the market.
5Guidance on expected test volumes for the next quarter.